Source - Alliance News

Poolbeg Pharma PLC on Monday said its build and optimisation of an artificial intelligence model of respiratory syncytial virus data is complete.

RSV is an infectious virus that affects around 50 million people per year, with 4 million global annual hospitalisations and 100,000 deaths in children under 5 years old. It can cause pneumonia and life-threatening breathing difficulties.

The AI model ‘can now commence its analysis, with results expected in the fourth quarter of 2022’, the London-based pharmaceutical company said. The model is tailored towards the firm’s human challenge trial, during which people are exposed to the virus in a controlled environment.

‘The directors believe this is the first time that AI analysis has been used to identify new drug targets and treatments for RSV using human challenge trial data,’ Poolbeg said. The ‘process will identify novel drug targets and treatments quicker and in a more cost-efficient manner than previously possible,’ the firm explained.

‘We hope that the results from this programme can help us to identify an effective treatment to address this significant public health threat,’ said Chief Executive Officer Jeremy Skillington.

Poolbeg added that is in a modelling-stage AI partnership with Tel Aviv, Israel-based CytoReason Ltd, which focuses on ‘drug target identification for influenza infections’.

Poolbeg Pharma shares were 8.2% higher at 6.17 pence each in London on Monday morning.

Copyright 2022 Alliance News Limited. All Rights Reserved.

Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJBell logo

Related Charts

Poolbeg Pharma PLC (POLB)

-0.15p (-1.55%)
delayed 13:04PM